Belantamab mafodotin

玛贝兰妥单抗

Report date: 2026/05/15 20:01:45
First In Class

Base Information

Drug NameBelantamab mafodotin
Drug Alias Name玛贝妥单抗anti-BCMA-ADC_GlaxoSmithKlineBELANTAMAB MAFODOTIN-BLMFBLENREPGSK-2857916 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > MC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAF payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsB-cell maturation protein inhibitors
TargetsTubulinB-cell maturation protein
Therapy Area/IndicationsAmyloidosisParaproteinemiasBlood Protein Disorders +[12] 
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaMultiple Myeloma
Original Approved Country/TerritoryUnited States
Original Approved Date2020/08/05
Country/TerritoryMainland China(BOAO LECHENG)CzechiaBelgium +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Texas Southwestern Medical CenterGlaxosmithkline Trading Services LtdGlaxosmithkline Plc +[10] 
Inactive CompaniesIqvia Rds (Shanghai) Co Ltd
Active IndicationsAmyloidosisParaproteinemiasBlood Protein Disorders +[9] 
Inactive IndicationsPlasmablastic LymphomaLymphoma, B-CellNeoplasms

Other Information

ATC CodeL01XC
Related LinksN/A